TCT is focused on improving the lives of patients with tafazzin deficiency. We advance our research through a combination of donations, grant support, and investment in the company.
TCT is a is a privately held corporation that seeks stakeholders who share our vision of improving human health through the development of breakthrough medicines. We encourage interested parties to learn more about TCT. For additional information contact our Investor Relations team by sending us a message using the contact page.
TCT is also very happy to accept donations to advance our research programs. If you are interested in making a donation please connect with us via the contact page, or send a donation to us at TransCellular Therapeutics, 4000 Mason Rd, Suite 302 Fluke Hall, Seattle Washington 98195. Your financial support is greatly appreciated as we develop a therapeutic for children with Barth Syndrome.